Diagnosis

biotech Diagnosing the m.3243A>G Mutation

Diagnosis brings together your history and suitable genetic tests. Blood testing alone can miss the variant.

event Editorial update September 2026
Print Summary

Diagnosis - quick summary

Think of it when

Diabetes and hearing loss, especially when relatives on your mother’s side are also affected, are reasons to discuss genetic testing. You do not need to be thin or have every feature for testing to be considered. Diabetes with sensorineural hearing loss and maternal transmission is a useful diagnostic clue. Body habitus, absent family history or incomplete phenotype should not alone exclude mitochondrial diabetes. 12

Test order

A low or negative blood result may need further investigation if your history suggests mitochondrial disease. The genetics team may use urine or another sample and a sensitive test. A negative blood result does not exclude low-level m.3243A>G. Sample selection and assay sensitivity should match age, phenotype and clinical suspicion; urine may improve detection. 2

Don’t stop too early

A low or negative blood result may need further investigation if your history suggests mitochondrial disease. The genetics team may use urine or another sample and a sensitive test. A negative blood result does not exclude low-level m.3243A>G. Sample selection and assay sensitivity should match age, phenotype and clinical suspicion; urine may improve detection. 2

Useful pages

Medication Safety, Emergency Letter, and the GP/New Doctor template on Sharing.

Explanation
Important medical disclaimer

This is a patient-written educational guide, not individualized medical advice. Use it to prepare for appointments and ask better questions, but make decisions about testing, referrals, and diagnostic next steps with qualified clinicians who know your case. If you are unwell or unsure how this applies to you, seek medical advice.

When to Suspect m.3243A>G

Diabetes and hearing loss, especially when relatives on your mother’s side are also affected, are reasons to discuss genetic testing. You do not need to be thin or have every feature for testing to be considered. Diabetes with sensorineural hearing loss and maternal transmission is a useful diagnostic clue. Body habitus, absent family history or incomplete phenotype should not alone exclude mitochondrial diabetes. 12

hearing
Hearing loss + diabetes

Hearing loss affecting both ears together with diabetes Diabetes with bilateral sensorineural hearing loss 12

glucose
Atypical diabetes

Diabetes with an unusual pattern; being lean can be a clue but is not required Atypical diabetes phenotype; normal body habitus or negative autoantibodies may support investigation 12

neurology
Stroke-like episode under 40

A brain scan may show changes that do not follow the area supplied by one blood vessel. MRI stroke-like lesions may extend beyond a single vascular territory. 34

emergency
Seizures + elevated lactate

Unexplained seizures, especially with other mitochondrial clues Unexplained epilepsy in a suggestive multisystem context 47

family_restroom
Maternal family pattern

Relatives on your mother’s side may have different combinations of hearing loss, diabetes or other symptoms. A maternal family history of variable multisystem features may support suspicion of mtDNA disease. 12

visibility_off
Eye or muscle involvement

Drooping eyelids, limited eye movements or unexplained muscle weakness Ptosis, progressive external ophthalmoplegia or unexplained myopathy 56

ecg_heart
Heart + hearing clues

Heart muscle disease together with hearing loss or other features Cardiomyopathy with sensorineural hearing loss or other multisystem features 56

genetics
Known family variant

A relative on your mother’s side with a confirmed m.3243A>G result A confirmed familial m.3243A>G variant in the maternal lineage 1516

Next Steps

If this pattern sounds familiar, the goal is simple: involve the right clinician and make the right testing easier to order.

1. Start with your GP

Bring your symptoms and family history to your usual doctor. They can discuss testing and the right referral. Initial assessment should document phenotype and maternal pedigree, with appropriate genetic testing or specialist referral. 2

Open doctor letter template

2. Ask for genetic testing

Blood is often tested first, but the best sample depends on your history and the laboratory test. If suspicion remains after a negative result, further testing may be needed. Blood testing is common initially; age, phenotype and assay detection limits guide additional urine or tissue testing. 2

3. Expect specialist referral

Your referral may involve genetics, neurology, metabolic medicine or a mitochondrial service, depending on local arrangements and symptoms. Referral pathways vary; clinical genetics and relevant organ or mitochondrial specialists can coordinate investigation. 2

info A normal blood test does not always end the story

A low or negative blood result may need further investigation if your history suggests mitochondrial disease. The genetics team may use urine or another sample and a sensitive test. A negative blood result does not exclude low-level m.3243A>G. Sample selection and assay sensitivity should match age, phenotype and clinical suspicion; urine may improve detection. 2

The Testing Pathway

Tests answer different questions; there is no single sequence that suits everyone. Sample choice and investigations are driven by phenotype and assay sensitivity, not a universal sensitivity ladder. 2

1
bloodtype

Blood Test

Often an initial sample. Low levels may be missed, especially with age or a less sensitive test. Common initial sample; age-related selection and assay detection limits can reduce sensitivity. 2

May miss MIDD
2
science

Urine Test

Can help detect m.3243A>G when blood gives a low or negative result. Urinary epithelial DNA can improve m.3243A>G detection in selected cases. 2

Recommended
3
biotech

Muscle Biopsy

An invasive test reserved for selected unresolved cases. Selective tissue investigation for unresolved diagnosis or functional evaluation; not routine first-line testing. 2

Gold standard

The Diagnostic Journey

Some people see several clinicians before their symptoms are linked. In a registry survey, many participants reported multiple investigations and earlier alternative diagnoses. That can be frustrating, and experiences differ. A registry survey documented a burdensome diagnostic pathway with multiple consultations and prior alternative diagnoses. Self-selection and self-reported diagnoses limit generalisation. 17

It can help to bring the different parts of your history together. Similar symptoms have many possible causes, so uncertainty during investigation does not mean your concerns are unimportant. Multisystem presentations can complicate recognition and differential diagnosis. A consolidated phenotype and pedigree can support assessment. 5617

You can advocate for yourself

  • Keep a written timeline of all symptoms - even those that seem unrelated (hearing, fatigue, migraine, diabetes)
  • Ask your GP or specialist directly: "Could this be mitochondrial?"
  • Request referral to a specialist metabolic or mitochondrial disease centre
  • If a blood result is negative, ask whether the sample and test were sensitive enough and what further testing is appropriate. After negative blood testing, review assay sensitivity, sample choice and residual clinical suspicion before selecting further investigations. 2
  • Bring a printed summary of your symptoms and family history to every appointment
  • Connect with patient organisations - they can help you find the right specialists

It is not always MELAS or MIDD

The same DNA change can produce different combinations of symptoms. Names such as MIDD and MELAS describe recognisable patterns, but they do not cover every person’s experience. m.3243A>G causes heterogeneous phenotypes, including syndromic, overlapping and non-syndromic presentations. 56

In one UK study of 129 people from affected families, researchers found several named patterns, mixed features and people without symptoms at assessment. That study illustrates variety; it does not predict which features you will develop. A UK cohort of 129 people from 83 families documented MELAS, MIDD, PEO, overlap, non-syndromic and clinically asymptomatic presentations. Its ascertainment limits population and prognostic inference. 56

Other possible presentations include: Additional m.3243A>G phenotypes include: 56

  • CPEO: gradually limited eye movements and drooping eyelids, sometimes with muscle problems. It is not a fixed middle stage between MIDD and MELAS. CPEO: progressive external ophthalmoplegia and ptosis, sometimes with myopathy; it is a phenotype, not a position on a severity ladder. 56
  • CPEO with other features: eye-movement problems alongside other organ involvement. CPEO-plus: ophthalmoplegia with additional systemic manifestations. 56
  • Overlap: a combination of features associated with more than one named pattern. Overlap phenotypes: features spanning recognised clinical syndromes. 56
  • Mainly muscle symptoms: weakness or low exercise tolerance may dominate. Myopathic presentation: weakness and exercise intolerance can predominate. 56
  • Mainly hearing loss: hearing may be the principal recognised problem. Isolated sensorineural hearing loss: auditory involvement may be the predominant recognised feature. 56
  • Mixed features: a combination that does not fit a named syndrome. Non-syndromic presentation: multisystem findings without a classical syndrome label. 56
  • No symptoms at assessment: some carriers have no recognised symptoms when tested. Clinically asymptomatic carriers: no recognised manifestations at the time of assessment. 56

In one UK study of 129 people from affected families, researchers found several named patterns, mixed features and people without symptoms at assessment. That study illustrates variety; it does not predict which features you will develop. A UK cohort of 129 people from 83 families documented MELAS, MIDD, PEO, overlap, non-syndromic and clinically asymptomatic presentations. Its ascertainment limits population and prognostic inference. 56

info Why this matters

A label can help organise care, but your actual symptoms and test results matter more than fitting a textbook description. Agree what monitoring you need. Management should follow phenotype and organ involvement rather than rely solely on a syndrome label. 568

A positive family test does not mean you already have disease symptoms. Discuss appropriate monitoring and what changes to report. A pathogenic variant result does not by itself establish symptomatic disease. Surveillance should be individualised after presymptomatic testing. 568

Blood Heteroplasmy

The report should say what sample was tested, which method was used and whether the variant was detected. It may also give the proportion of changed DNA. Reports should specify sample type, variant detection, assay limitations and heteroplasmy quantification where available. 2

Report detail Report detail Interpretation
Variant detected Variant detected Confirms detection in that sample; symptoms still need clinical interpretation. Variant detection must be interpreted in the context of phenotype and sampled tissue. 256
Measured percentage Measured percentage Describes that sample, not a severity score or a MIDD/MELAS cut-off. Sample heteroplasmy is not a deterministic severity measure or syndrome threshold. 614
Low-level result Low-level result Can be important; the laboratory and specialist assess reliability and meaning. Interpret with assay detection limits, confirmation requirements and phenotype. 2
Not detected Not detected May need further testing if clinical suspicion remains. Does not exclude disease when assay sensitivity or sample type is limiting. 2

Urine Heteroplasmy

A low or negative blood result may need further investigation if your history suggests mitochondrial disease. The genetics team may use urine or another sample and a sensitive test. A negative blood result does not exclude low-level m.3243A>G. Sample selection and assay sensitivity should match age, phenotype and clinical suspicion; urine may improve detection. 2

check_circle Advantages
  • Can contain a higher mutation level than blood May have higher m.3243A>G heteroplasmy than blood 2
  • Blood and urine change differently with age Age-related selection differs between tissues 2
  • Collected without a biopsy Non-invasive sampling 2
  • Can help after a negative blood test May detect variants not detected in blood 2
  • Still not a forecast of your health Not a definitive individual prognostic biomarker 2614
info Limitations
  • The sample needs enough usable cells DNA yield and cellular composition affect analysis 2
  • Follow the laboratory’s collection instructions Use the laboratory’s validated collection protocol 2
  • Your team can check local testing options Assay availability depends on the laboratory 2
  • A sensitive test is still important Very low heteroplasmy can remain below detection limits 2

Muscle Biopsy

A muscle biopsy may help when other tests do not resolve a strong clinical suspicion. It is invasive, so specialists weigh what it is likely to add. Muscle can support genetic, histological and functional investigation after unresolved non-invasive testing. Biopsy is no longer a routine first-line investigation. 2

Histochemistry

A specialist can examine the pattern of muscle fibres for signs that support mitochondrial dysfunction. Histology and histochemistry may provide supportive evidence of mitochondrial dysfunction; results require integrated interpretation. 2

Biochemistry

The laboratory may measure how the muscle’s energy-producing machinery works. Respiratory-chain enzyme analysis may contribute functional evidence in selected cases. 2

Molecular

DNA testing on muscle answers questions about that tissue. It still cannot measure the mutation level in every organ. Muscle mtDNA analysis may improve detection or interpretation, but tissue heteroplasmy is not a whole-body measurement. 2614

Brain MRI

A stroke-like episode can cause headache, vision changes, weakness, speech difficulty, confusion or seizures. Symptoms may evolve over hours or days. Seek emergency help for new neurological symptoms; you cannot tell the cause safely at home. Stroke-like episodes can produce evolving focal deficits, encephalopathy and seizures. Acute assessment must consider vascular stroke and other causes alongside mitochondrial disease. 478

Stroke-like Lesions

Changes may involve the brain’s outer layer and extend beyond a single blood-vessel area. Cortical stroke-like lesions may have non-territorial distribution and evolving spread. 34

Diffusion Pattern

Different scan sequences help the team understand the changes; one scan feature is not enough to diagnose MELAS. MRI sequences are interpreted together with the clinical course; no isolated imaging feature establishes MELAS. 34

Atrophy & Calcification

Scans may also show lasting changes from earlier illness. Imaging may demonstrate chronic structural consequences of prior neurological disease. 418

MR Spectroscopy

Additional specialised scans may help in selected cases. The team decides which questions need answering. Specialist imaging and biochemical investigations may provide supportive evidence within an integrated diagnostic assessment. 247

neurology MRI tip

Different scan patterns: changes may cross the usual boundaries of blood-vessel areas. Distribution: stroke-like lesions may be non-territorial; this does not exclude coexisting vascular disease. 34

Other Investigations

Use this table to discuss your care plan. The tests and timing depend on your symptoms, past results and other health conditions. Surveillance is individualised to phenotype, baseline abnormalities and evolving symptoms. The table is a discussion aid, not a fixed testing protocol. 8

water_drop
Blood & CSF lactate

Lactate can be raised; a single result does not diagnose mitochondrial disease. Interpret lactate with sampling conditions, acid–base status and other possible causes. 47

ecg_heart
ECG & Echocardiogram

The heart muscle or its electrical system can be affected. A person may need checks even before symptoms become obvious. Cardiomyopathy and conduction or rhythm abnormalities can occur in mitochondrial disease; symptoms may not reflect the full degree of involvement. 8

hearing
Audiometry

Hearing loss often affects both ears and may worsen over time. High-pitched sounds can be affected early, but hearing-test patterns differ between people. Hearing loss is commonly bilateral, progressive and sensorineural. High-frequency involvement is frequent, but onset, audiometric configuration and progression vary. 910

visibility
Dilated Fundoscopy

Changes can develop in the macula, the part of the retina used for detailed central vision. They may be visible on an eye test before you notice symptoms. Macular pattern dystrophy is associated with MIDD and may be detected despite relatively preserved acuity. The extent and functional consequences vary. 811

glucose
HbA1c & Glucose

MIDD can reduce the amount of insulin the pancreas makes. The body may also respond less well to insulin. It is a genetic form of diabetes, and its treatment needs can change over time. Mitochondrial dysfunction can impair beta-cell insulin secretion; insulin resistance may also contribute. MIDD is a monogenic diabetes phenotype, with variable residual insulin secretion and treatment requirements. 112

nephrology
Renal Function

Kidney problems can affect the filters or the small tubes that control water and minerals. Protein in urine can be one clue. Renal phenotypes include glomerular disease such as FSGS and tubular dysfunction. Proteinuria may be a presenting feature. 813

Reading Your Genetic Report

Once testing is done, you'll receive a report that may feel overwhelming. Here's how to make sense of it - and what questions to ask your specialist.

code

Variant Notation

The name m.3243A>G identifies the DNA change; MT-TL1 is the gene involved. Ask your team to explain any unfamiliar notation. The variant notation m.3243A>G identifies a mitochondrial nucleotide substitution in MT-TL1. 719

percent

Heteroplasmy Level

Mutation level matters, but it is not a simple health score. A percentage from blood or urine does not show exactly what is happening in the brain, heart or muscles. Tissue heteroplasmy contributes to biochemical dysfunction, but peripheral measurements do not directly quantify every affected organ or determine phenotype. 614

experiment

Which Tissue Was Tested?

Check which tissue was tested and whether the report lists a detection limit. Ask if the result answers the question your team was investigating. Sample type and validated assay detection limits are essential for interpreting positive and negative results. 2

verified

Variant Classification

m.3243A>G is a recognised disease-associated variant. Its presence does not tell you exactly what symptoms you will develop. If wording is unclear, ask the genetics team to interpret the complete report. m.3243A>G is an established pathogenic mtDNA variant with variable expression. Classification and genotype–phenotype interpretation should be explained by the reporting laboratory or genetics team. 2719

Questions to ask your specialist

  • What was my heteroplasmy level, and in which tissue?
  • Should I have urine or muscle tested as well?
  • Based on my heteroplasmy level and symptoms, where do I sit on the m.3243A>G spectrum, and what should I be monitored for?
  • Should my maternal relatives be offered testing?
  • What monitoring do I need, and how often?
  • Which medications should I avoid, and do I need a medical alert card?
See the full list of questions to ask your doctor

What happens next?

A diagnosis can bring relief, worry or both. Take the information at your own pace. Follow any urgent instructions from your care team, and seek emergency help for new severe symptoms. A diagnosis can bring relief, worry or both. Take the information at your own pace. Follow any urgent instructions from your care team, and seek emergency help for new severe symptoms.

Useful next steps are arranging specialist follow-up, reviewing medicines and discussing whether relatives would benefit from counselling or testing. Coordinate surveillance, genotype-informed medication review and appropriate cascade counselling/testing. 815162021

emergency

When to seek urgent medical care

Severe or new symptoms need prompt medical assessment. Use your personal emergency plan and share your diagnosis with the treating team. New neurological symptoms or severe systemic illness require prompt assessment and the individual emergency plan. 48

warning Seek urgent medical care now if:
  • New weakness, speech or vision changes, confusion, a severe new headache or a new seizure. Acute focal deficits, visual disturbance, encephalopathy, severe new headache or new seizures. 48
  • Persistent vomiting, inability to keep food or fluids down, or rapid deterioration. Persistent emesis, inability to maintain intake or rapid clinical deterioration. 8
  • Chest pain, fainting or severe breathing difficulty. Chest pain, syncope or severe dyspnoea. 48
  • Severe abdominal pain or swelling with repeated vomiting. Severe abdominal pain or distension with recurrent emesis. 4822
  • Severe unexpected muscle pain or weakness, especially with dark urine. Marked unexpected myalgia or weakness, particularly with possible myoglobinuria. 23

Bring your personalised emergency letter, medicine and allergy list, and specialist contacts. Clinicians need to consider mitochondrial and other possible causes. Provide the individual emergency plan, medication reconciliation, allergies and specialist contacts; maintain a broad differential diagnosis. 8

medication Medication Safety Guide description Emergency Letter

References

23 sources

Sources for the information on this page.

  1. Chanoine JP, Thompson DM, Lehman A. (2025). Diabetes Associated With Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes. ReviewDOIFull text↑ Back to text
  2. Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, Knowles CVY, Patel Y, Hodsdon P, Baines JP, Blakely EL, Polke J, Taylor RW, Fratter C. (2023). Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. European journal of human genetics : EJHG. Clinical guidanceDOIFull text↑ Back to text
  3. Tang H, Liu J, Cai X, Leng F, Hu J, Zhao Y, Wang Z, Yu L. (2026). Analysis of acute stroke-like lesions in MELAS: Distribution, potential boundaries and spreading pattern. Neuroimage. Reports. Research articleDOIFull text↑ Back to text
  4. Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  5. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. Research articleDOI↑ Back to text
  6. Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. Research articleDOIFull text↑ Back to text
  7. El-Hattab AW, Adesina AM, Jones J, Scaglia F. (2015). MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular genetics and metabolism. ReviewDOI↑ Back to text
  8. Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. Clinical guidanceDOIFull text↑ Back to text
  9. Sue CM, Lipsett LJ, Crimmins DS, Tsang CS, Boyages SC, Presgrave CM, Gibson WP, Byrne E, Morris JG. (1998). Cochlear origin of hearing loss in MELAS syndrome. Annals of neurology. Observational studyDOI↑ Back to text
  10. Chinnery PF, Elliott C, Green GR, Rees A, Coulthard A, Turnbull DM, Griffiths TD. (2000). The spectrum of hearing loss due to mitochondrial DNA defects. Brain : a journal of neurology. Research articleDOI↑ Back to text
  11. Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, Caillat-Zucman S, Froguel P, Paquis-Fluckinger V, Gaudric A, Guillausseau PJ. (1999). Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology. Observational studyDOI↑ Back to text
  12. Chaudhry A, Thompson DM, Chanoine JP. (2026). Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm. Diabetes, obesity & metabolism. ReviewDOIFull text↑ Back to text
  13. Guéry B, Choukroun G, Noël LH, Clavel P, Rötig A, Lebon S, Rustin P, Bellané-Chantelot C, Mougenot B, Grünfeld JP, Chauveau D. (2003). The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. Journal of the American Society of Nephrology : JASN. Research articleDOI↑ Back to text
  14. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. Research articleDOIFull text↑ Back to text
  15. Smeets HJM, Sallevelt SCEH, Herbert M. (2023). Reproductive options in mitochondrial disease. Handbook of clinical neurology. ReviewDOI↑ Back to text
  16. Castelluccio N, Spath K, Li D, De Coo IFM, Butterworth L, Wells D, Mertes H, Poulton J, Heindryckx B. (2025). Genetic and reproductive strategies to prevent mitochondrial diseases. Human reproduction update. ReviewDOI↑ Back to text
  17. Grier J, Hirano M, Karaa A, Shepard E, Thompson JLP. (2018). Diagnostic odyssey of patients with mitochondrial disease: Results of a survey. Neurology. Genetics. Research articleDOIFull text↑ Back to text
  18. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. (2011). Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. Research articleDOIFull text↑ Back to text
  19. Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. Research articleDOI↑ Back to text
  20. De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti C, McFarland R, Ng YS, O'Callaghan M, Pitceathly RDS, Rahman S, Russel FGM, Varhaug KN, Schirris TJJ, Mancuso M. (2020). Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus. Journal of inherited metabolic disease. Clinical guidanceDOIFull text↑ Back to text
  21. Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  22. de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. (2015). Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. The Netherlands journal of medicine. Research article↑ Back to text
  23. Centers for Disease Control and Prevention / NIOSH (accessed 2026). Signs and Symptoms of Rhabdomyolysis . Official guidance↑ Back to text

Browse the research library for papers grouped by topic.

Keep exploring

Related pages

Related pages you may find interesting.

arrow_forwardQuestions for Your Doctorarrow_forwardEmergency Letterarrow_forwardDaily Life
chatGive feedback
favorite Support